Lung Cancer Soup to Nuts

"Supported by an educational grant from Merck"

This presentation will discuss lung cancer from start to finish. I will focus on needs of the primary and acute care provider. Screening will be covered in detail and how it affects outcomes. Staging and treatments by stage will also be reviewed. Treatments for advanced stage lung cancer including, chemotherapy, immunotherapy and targeted therapies will be addressed and there will be an emphasis on the common toxicities that primary care and inpatient providers may encounter and how to manage these.

*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.0 Contact Hours; 0.75 are Pharmacology
This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/2026 . PAs should only claim credit commensurate with the extent of their participation. 
Expiration Date: December 31, 2026

$10.00

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

- Identify eligible patients for lung cancer screening and cover all of the Medicare requirements to initiate CT scan screening

- Understand the stages of lung cancer and the treatment modalities associated with each stage

- Identify and manage common toxicities associated with treatments for lung cancer

CE/CME INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 0.75 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/2026 . PAs should only claim credit commensurate with the extent of their participation.

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURES

Faculty

Contributing faculty, Beth Sandy, MSN, CRNP, FAPO has disclosed:

Merck Speaker’s Bureau Lung Cancer Pembrolizumab
Lilly Speaker’s Bureau Biomarker Testing in Oncology No drug, unbranded
Astra Zeneca Speaker’s Bureau Lung Cancer Osimertinib, Durvalumab
Amgen Speaker’s Bureau Lung Cancer Tarlatamab, Sotorasib
Takeda Speaker’s Bureau Lung Cancer Brigatinib, relationship ended 2024
Jazz Speaker’s Bureau Lung Cancer Lurbinectidin
Janssen Advisory Board Lung Cancer Amivantamab and Lazertinib
Pfizer Advisory Board Lung Cancer Lorlatinib

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.